Pathogenesis of cardiotoxicity induced by anthracyclines
- PMID: 16781283
- DOI: 10.1053/j.seminoncol.2006.04.020
Pathogenesis of cardiotoxicity induced by anthracyclines
Abstract
Anthracyclines are potent anti-neoplastic drugs used in the treatment of solid and hematologic cancers. However, their use is limited by cumulative dose-related cardiotoxic adverse effects, which are progressive and irreversible from the first dose. Clinical trial data have shown that anthracycline cardiotoxicity is associated with slowly progressive deterioration of cardiac function, which continues for years after treatment cessation. Cardiac damage has been shown at cumulative doses as low as 200 mg/m2, well below levels currently assumed to induce injury. The widespread use of anthracyclines in childhood leukemia has resulted in an improved long-term prognosis; however, these patients are subsequently at high risk of developing long-term cardiac damage, with studies suggesting as many as 65% of survivors of childhood leukemia will develop cardiac abnormalities. Middle aged and elderly patients who are prone to cardiac disease may be more vulnerable to the cardiotoxic effects of anthracyclines. Therapies or strategies to prevent anthracycline-induced cardiotoxicity are essential; ideally, these should be initiated at the beginning of anthracycline therapy to reduce the possibility of cardiac damage and to ensure the optimal use of chemotherapy.
Similar articles
-
Exposure to anthracyclines during childhood causes cardiac injury.Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. doi: 10.1053/j.seminoncol.2006.04.019. Semin Oncol. 2006. PMID: 16781284 Review.
-
Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.Semin Oncol. 2006 Jun;33(3 Suppl 8):S15-21. doi: 10.1053/j.seminoncol.2006.04.022. Semin Oncol. 2006. PMID: 16781285 Review.
-
Anthracycline-induced cardiotoxicity in adult hematologic malignancies.Semin Oncol. 2006 Jun;33(3 Suppl 8):S22-7. doi: 10.1053/j.seminoncol.2006.04.021. Semin Oncol. 2006. PMID: 16781286 Review.
-
Anthracycline cardiotoxicity in long-term survivors of childhood cancer.Cardiovasc Toxicol. 2007;7(2):122-8. doi: 10.1007/s12012-007-0006-4. Cardiovasc Toxicol. 2007. PMID: 17652816 Review.
-
Anthracycline cardiotoxicity in childhood.Pediatr Hematol Oncol. 2008 Jun;25(4):261-81. doi: 10.1080/08880010802016649. Pediatr Hematol Oncol. 2008. PMID: 18484471 Review.
Cited by
-
Thioredoxin Decreases Anthracycline Cardiotoxicity, But Sensitizes Cancer Cell Apoptosis.Cardiovasc Toxicol. 2021 Feb;21(2):142-151. doi: 10.1007/s12012-020-09605-2. Epub 2020 Sep 3. Cardiovasc Toxicol. 2021. PMID: 32880787 Free PMC article.
-
Liposomal daunorubicin as treatment for Kaposi's sarcoma.Int J Nanomedicine. 2007;2(3):277-88. Int J Nanomedicine. 2007. PMID: 18019828 Free PMC article. Review.
-
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy.Br J Haematol. 2011 Sep;154(5):579-89. doi: 10.1111/j.1365-2141.2011.08786.x. Epub 2011 Jun 28. Br J Haematol. 2011. PMID: 21707585 Free PMC article. Clinical Trial.
-
An integrated control strategy for the fermentation of the marine-derived fungus Aspergillus glaucus for the production of anti-cancer polyketide.Mar Biotechnol (NY). 2012 Dec;14(6):665-71. doi: 10.1007/s10126-012-9435-6. Mar Biotechnol (NY). 2012. PMID: 22286337
-
Mapping genes that contribute to daunorubicin-induced cytotoxicity.Cancer Res. 2007 Jun 1;67(11):5425-33. doi: 10.1158/0008-5472.CAN-06-4431. Cancer Res. 2007. PMID: 17545624 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
